<DOC>
	<DOC>NCT02960880</DOC>
	<brief_summary>The aim of this study is to assess the real world comparative effectiveness of Rivaroxaban prescribed in non-valvular atrial fibrillation (NVAF) routine care patients in Germany.</brief_summary>
	<brief_title>Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<criteria>First dispense date of Rivaroxaban (15mg or 20mg PZN based) or Phenprocoumon (PZN based) between January 1, 2012 and December 31, 2015 At least two verified outpatient diagnoses or one inpatient diagnosis (main or secondary diagnosis) of NVAF (ICD10 GM I48.0/I48.1/I48.2/I48.9) in the individual time frame of 4 quarters before the index date (preindex period) or within the index quarter Patients will be required to have 4 quarters of enrollment for the assessment of baseline characteristics and be observable and insured in the database for at least one day after their individual index date (postindex period) â‰¥ 18 years of age Patients with valvular AF [4 quarters prior to the index date] Pregnancy [4 quarters prior to index date] Malignant cancers [4 quarters prior to the index date or "condition after"] Transient cause of AF [4 quarters prior to index date] Patients with VTE (pulmonary embolism or DVT) [60 days before index] Patients with major surgery defined as hip or knee replacement [60 days before index] Prescriptions of OACs (Rivaroxaban, VKA, Dabigatran, Apixaban) before index date [4 quarters prior to index date] Patients receiving more than one anticoagulant substance (Apixaban, Dabigatran, Rivaroxaban or Phenprocoumon) or more than one dosage of a substance on the index date For sensitivity analysis : Patient with any of the events defined in the combined endpoints [4 quarters prior to index date or "condition after" Patients with dialysis [4 quarters prior to index date]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rivaroxaban, Phenprocoumon, retrospective cohort study, Non-Valvular Atrial fibrillation, NVAF</keyword>
</DOC>